<DOC>
	<DOC>NCT02632747</DOC>
	<brief_summary>This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril in patients with type 1 diabetes.</brief_summary>
	<brief_title>Empagliflozin and ACEi Effects on Hyperfiltration in Type 1 Diabetes (BETWEEN Study)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Signed and dated written informed consent. Male or female patients diagnosed with type 1 diabetes at least 6 months prior to informed consent. Use of and be willing to continue throughout the duration of the trial either: multiple daily injections of insulin OR continuous subcutaneous insulin infusion of any insulin type, with at least 3 months experience HbA1c of 6.5 11% Age at least 18 years of age Body mass index of 18.5 to 35 kg/m2 Estimated glomerular filtration rate greater than or equal to 60 ml/min/1.73m2 Blood pressure greater than 90 /60 mmHg and less than or equal to 140 / 90 mmHg Use of a highly effective method of contraception. Further inclusion criteria apply Exclusion criteria: Treatment with an antihyperglycaemic agent within 3 months prior to visit 1 occurrence of severe hypoglycaemia within 3 months prior to visit 1 hypoglycaemic unawareness within 3 months prior to visit 1 occurrence of diabetic ketoacidosis within 3 months of visit 1 and until visit 3 Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>